Efficacy and Safety of Lebrikizumab in moderate to severe atopic Dermatitis: Results of two randomized, double-blind, placebo-controlled phase III Studies (ADvocate1 and ADvocate2) at 52 Weeks

被引：0
|
作者：
Blauvelt, A. [1 ]
Thyssen, J. P. [2 ]
Guttman-Yassky, E. [3 ]
Bieber, T. [4 ]
Serra-Baldrich, E. [5 ]
Simspon, E. [6 ]
Rosmarin, D. [7 ]
Diemert, S. [8 ]
Elmaraghy, H. [9 ]
Silverberg, J. [10 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Univ Hosp Bonn, Bonn, Germany
[5] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[6] Oregon Hlth & Sci Univ, Portland, OR USA
[7] Tufts Univ, Sch Med, Boston, MA USA
[8] Almirall Hermal GmbH, Reinbek, Germany
[9] Eli Lilly & Co, Indianapolis, IN USA
[10] George Washington Univ, Sch Med & Hlth Sci, Washington, OR USA
来源：
ALLERGOLOGIE | 2023年 / 46卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P4.01
引用
收藏
页码：530 / 530
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: results from the pivotal phase III, randomized, double-blind, placebo-controlled AD Up study
    Reich, K.
    Teixeira, H. D.
    De Bruin-Weller, M.
    Bieber, T.
    Soong, W.
    Kabashima, K.
    Werfel, T.
    Zeng, J.
    Huang, X.
    Hu, X.
    Ladizinski, B.
    Chu, A. D.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E59 - E60
  • [32] Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial
    Glatt, Sophie
    Jemec, Gregor B. E.
    Forman, Seth
    Sayed, Christopher
    Schmieder, George
    Weisman, Jamie
    Rolleri, Robert
    Seegobin, Seth
    Baeten, Dominique
    Ionescu, Lucian
    Zouboulis, Christos C.
    Shaw, Stevan
    JAMA DERMATOLOGY, 2021, 157 (11) : 1279 - 1288
  • [33] Efficacy and safety of itopride in functional dyspepsia: Results of two phase III multicentre, randomized, double-blind, placebo-controlled trials
    Talley, Nicholas J.
    Tack, Jan
    Ptak, Theadore
    Gupta, Rajendra
    Giguere, Monique
    GASTROENTEROLOGY, 2007, 132 (04) : A93 - A93
  • [34] A phase 2b, randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of ANB032 in the treatment of moderate-to-severe atopic dermatitis
    Ehst, B.
    Silverberg, J.
    Lizzul, P.
    Luu, K.
    Papacharalambous, J.
    Raina, P.
    Randazzo, B.
    Sibley, C.
    Guttman-Yassky, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S347 - S347
  • [35] Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase III, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
    Blauvelt, A.
    Wollenberg, A.
    Pink, A.
    Peris, K.
    Armstrong, A.
    Spelman, L.
    Saeki, H.
    Lynde, C.
    Herranz, P.
    Barbarot, S.
    Simpson, E.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E110 - E111
  • [36] Double-blind placebo controlled randomized comparative study of effectiveness and safety of Lactofiltrum for atopic dermatitis in moderate and severe exacerbations
    Zakirova, S.
    ALLERGY, 2015, 70 : 408 - 408
  • [37] Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
    Ebisawa, Motohiro
    Kataoka, Yoko
    Tanaka, Akio
    Nagao, Mizuho
    Laws, Elizabeth
    Mortensen, Eric
    Nawata, Hisakatsu
    Arima, Kazuhiko
    Watanabe, Daisuke
    Lu, Xin
    Maloney, Jennifer
    Dubost-Brama, Ariane
    Bansal, Ashish
    Yahata, Kenji
    ALLERGOLOGY INTERNATIONAL, 2024, 73 (04) : 532 - 542
  • [38] Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study
    Igarashi, Atsuyuki
    Katsunuma, Toshio
    Matsumura, Takayo
    Komazaki, Hiroshi
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 190 (01) : 20 - 28
  • [39] Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study
    Seo, Seong Jun
    Shin, Bong Seok
    Lee, Joo-Heung
    Jeong, Haeyoun
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 807 - 817
  • [40] Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial
    Guttman-Yassky, E.
    Bahadori, L.
    Brooks, L.
    Clark, K. L.
    Grindebacke, H.
    Ho, C. N.
    Katial, R.
    Pham, T. -H.
    Walton, C.
    Datto, C. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (10) : E1211 - E1214
12345